Management Team
David Akunis
CEO
Close
David Akunis
CEO
David Akunis brings over 30 years of experience in corporate management and venture capital investment, with a focus on Life-Science and MedTech sectors. From 2010 to 2024, he served as Managing Partner at Medvest UK Venture Fund, overseeing investments in Israeli Life-Science companies. David has also held leadership roles as General Manager and CEO at several prominent MedTech and Pharma startups, including Flometrica Ltd., Coerulius Ltd., and Exerflow Medical Ltd. He has a proven track record in managing complex businesses, technology-driven projects, and supporting global.
Inna Martin
Director and COO
Close
Inna Martin
Director and COO
Inna brings over 20 years of experience in venture financing, portfolio management and M&As. Prior to joining Revium, Inna co-founded SPAS™, an innovative cardiovascular solution which is now being adopted by several leading clinics in the US. Inna served as a managing partner at a $760 million sovereign fund focused on healthcare innovation where she managed a portfolio of medical devices and pharmaceutical companies with a combined exit value of over $1.5 billion. Inna has served on the boards of multiple US and Israeli startup companies.
Dr. Erez Koren
CTO
Close
Dr. Erez Koren
CTO
Erez joined Revium in 2023, bringing over 15 years of experience in pharma and biotech R&D. He previously served as Head of Early-Stage CMC at Clexio Biosciences, where he was responsible for formulation development and phase 1-2 regulatory submissions. Prior to that, Erez led the Innovative R&D Pharma Lab at Teva Pharmaceuticals. He also led CMC activities at Lipocure Ltd. and contributed to the FDA submission and approval of a liposomal drug product (ANDA). Erez holds a Ph.D. in pharmaceutical sciences and completed postdoctoral training at Northeastern University (Boston, MA). Erez has authored over 40 peer-reviewed papers and contributed to five patent applications.
Amir Avraham
Internal Audit
Close
Amir Avraham
Internal Audit
Amir Avraham is a certified accountant (CPA) with over 15 years of experience in high-tech finance, accounting, mergers & acquisitions, and tax. He currently serves as CFO & General Manager at OCON Therapeutics, a prominent Israeli medical startup that is developing a unique drug-device product. Prior to joining Revium, Amir worked at Van Leer Technology Ventures and Deloitte & Touche. His expertise includes strategic planning, profitability analysis, project management, and driving business growth in multinational organizations.
Yoram Druker
VP Business Development
Close
Yoram Druker
VP Business Development
Yoram Drucker is a serial entrepreneur with over 25 years of experience in business development, fundraising, and executive roles in the biotechnology sector. He co-founded and contributed to the development of three publicly-traded biotech companies, including Brainstorm (NASDAQ:BCLI), where he served as COO and CEO, and Pluri Biotech (NASDAQ: PLUR; TLV:PLUR).
Arie Gordashnikov
CFO
Close
Arie Gordashnikov
CFO
Arie brings to Revium 14 years of experience in accounting, audit and financial management of hi-tech and biotechnology companies. Since 2018, he serves as Head of IPO & M&A Department at a one of the leading accounting firms of Israel. Prior to that, Mr. Gordashnikov served as an Audit Manager at Ernst & Young Israel. Mr. Arie is licensed CPA since 2012 and has extensive experience in RCC and PCAOB reporting.
Board of Directors
Inna Martin
Director and COO
Close
Inna Martin
Director and COO
Inna brings over 20 years of experience in venture financing, portfolio management and M&As. Prior to joining Revium, Inna co-founded SPAS™, an innovative cardiovascular solution which is now being adopted by several leading clinics in the US. Inna served as a managing partner at a $760 million sovereign fund focused on healthcare innovation where she managed a portfolio of medical devices and pharmaceutical companies with a combined exit value of over $1.5 billion. Inna has served on the boards of multiple US and Israeli startup companies.
Moti Jacobson
Director
Close
Moti Jacobson
Director
Moti Jacobson is a seasoned CFO with extensive experience in business development and financial management, who has established several companies in various European countries and in China. Prior to joining the Board of Directors of Revium, he served in several senior management positions at multinational companies such as IBM, PepsiCo, and Ness Technologies, where he was responsible for financial operations management and large-scale M&A activities. Moti currently serves as the CFO of Skylock and Beesense Sensors.
Bernard Bartal
Chairman
Close
Bernard Bartal
Chairman
Bernard is a seasoned entrepreneur with an exceptional track record in life science innovation. He is a founder, and an executive board member, of various life sciences companies, including AImmune (acquired by Nestle), Exonavis Therapeutics, Dien-A Molecular Biology, Biotic Therapeutics, and Advanced Concepts in Biology.
Matti Munk
Director
Close
Matti Munk
Director
Matti Munk brings to Revium over 25 years of experience in corporate finance, banking, capital raising, and directorships for Israeli and UK corporations. He currently serves as Regional Director at Euro Exim Bank. Matti is a former manager of international private banking at Mercantile Discount Bank and Bank of Jerusalem, where he was in charge of international mortgage departments and led cross-border compliance teams.
Yoram Druker
VP Business Development
Close
Yoram Druker
VP Business Development
Yoram Drucker is a serial entrepreneur with over 25 years of experience in business development, fundraising, and executive roles in the biotechnology sector. He co-founded and contributed to the development of three publicly-traded biotech companies, including Brainstorm (NASDAQ:BCLI), where he served as COO and CEO, and Pluri Biotech (NASDAQ: PLUR; TLV:PLUR).
Scientific Advisory Board
Prof. Yechezkel
Barenholz
Close
Prof. Yechezkel Barenholz
Prof. Yechezkel Barenholz is a world-renowned professor of biochemistry at the Hebrew University of Jerusalem and the head of the Liposome and Membrane Research Lab. He has co-authored over 440 publications with more than 47,700 citations and holds over 55 patents, more than half of which have been licensed. Prof. Barenholz is one of the key inventors of Doxil®, the first FDA-approved nano-drug for cancer treatment. He has co-founded six startups and is currently developing six additional liposomal drugs for various medical applications. His work bridges biology, nanotechnology, and medicine.
Prof. Itzhak
Haviv
Close
Prof. Itzhak Haviv
Prof. Itzhak Haviv has co-authored 143 peer-reviewed papers, with 8,661 citations and an H-index of 43. His cancer research career includes postdoctoral work at UC Berkeley and founding one of the first precision medicine services at Peter MacCallum Cancer Centre. He co-founded the NICTA life science program in Australia and Israel’s fifth medical school, playing a key role in biomedical research and COVID-19 pandemic control strategies.
Prof. Allon
Moses
Close
Prof. Allon Moses
Prof. Allon E. Moses is a renowned leader in infectious diseases, clinical microbiology, and hospital epidemiology. He served as Chairman of the Department of Clinical Microbiology and Infectious Diseases at Hadassah University Hospital in Jerusalem and President of the Israeli Society of Infectious Diseases, contributing significantly to public health and medical research. His expertise in infectious disease management, antimicrobial resistance, and hospital epidemiology has influenced national infection control policies in several countries across Africa and Asia, improving patient safety and healthcare standards. As a Professor of Clinical Microbiology, he remains dedicated to mentoring future medical professionals and advancing global infectious disease research.
Dr. Ronen
Brenner
Close
Dr. Ronen Brenner
A senior oncologist with over 20 years of experience in clinical research, drug development, and medical education. As Head of the Oncology Institute at Wolfson Medical Center, Dr. Brenner leads cancer treatment programs, oversees clinical trials, and collaborates with pharmaceutical companies. His expertise in clinical strategy and patient care has contributed to advancing oncology treatments and publishing impactful research.
